Nextech Invest Ltd of Switzerland has led a $25 million Series B financing round for a young US biotech company that is developing kinase inhibitors for genomically-defined cancer subsets. Blueprint Medicines Corp is located in Cambridge, Mass. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
